This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

2011 Bond Ratings: Upgrades, Downgrades

Life Science Industry

Rating Action: Outlook Raised to Positive From Stable

Rating Date: Apr. 8

Moody's revised its outlook for the U.S. life science industry to positive from stable.

"The revision reflects Moody's belief that the sector's operating profits will rise 5% to 7% over the next 12 to 18 months, driven by increased spending on scientific research and development and testing worldwide," said Moody's.

Moody's said much of the growing demand for the tools and equipment that life science companies make and distribute comes from industrial companies, which are benefiting the most from the global recovery.

Industrial companies account for about 25% of the life science sector's revenues.

Life science stocks were trading in mixed territory on Apr. 12. Allergan (AGN - Get Report) was falling 0.5% to $74.85 and AstraZeneca (AZN - Get Report) was trading sideways at $48.69. Merck (MRK - Get Report) was up 0.3% to $33.68 and Pfizer (PFE - Get Report) was 0.9% lower at $20.48. Novartis (NVS - Get Report) was rising 0.2% to $55.30 and GlaxoSmithKline (GSK - Get Report) was increasing 0.5% to $40.21.
2 of 53

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG
AGN $328.87 0.00%
AZN $33.74 0.00%
GSK $43.59 0.00%
MRK $58.52 0.00%
NVS $103.18 0.00%

Markets

Chart of I:DJI
DOW 17,745.98 -5.41 -0.03%
S&P 500 2,108.63 +0.06 0.00%
NASDAQ 5,128.7850 +17.0520 0.33%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs